Uncategorized
Lexaria Applauds Eli Lilly’s Foundayo(TM) Drug Approval
Kelowna, BC
Lexaria Bioscience Corp., (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to recognize that the US Food and Drug Administration (“FDA”) has approved Eli Lilly and Company’s® Foundayo™ glucagon-like peptide-1 (“GLP-1”) agonist (orforglipron) oral tablet for adult use in controlling obesity and weight-related medical conditions.
“This latest approval from the FDA expands choices for Americans searching for the right weight control drug that best suits their needs,” said Richard Christopher, CEO of Lexaria Bioscience Corp. “Expanded choices within the historically limited oral weight-loss drug category increases opportunities for Lexaria to partner with the leading companies in the pharmaceutical industry to implement DehydraTECH™ technology to improve patient experiences including through the potential for reduced side effects.”
The recent FDA approval of Foundayo™ follows both the December 2025 approval of Wegovy® tablets for weight loss and the September 2019 approval of Rybelsus® tablets for diabetes, bringing the total number of FDA approved GLP-1 oral brand offerings to 3. In 2025, worldwide revenues of the sole oral offering within the GLP-1 category (Rybelsus®) totaled $3.5B. This represented less than 5% of the 2025 worldwide GLP-1 revenue total, highlighting the tremendous upside growth potential that oral options have within the GLP-1 marketplace.
As Lexaria recently announced, its forward-looking strategic plans for the GLP-1 sector continue to be centered around improving the patient experience while using these drugs for indications including but not limited to diabetes and weight loss, primarily through the reduction of unwanted side effects.
In Eli Lilly’s clinical trial, patients taking Foundayo™ (orforglipron) for the full study duration of 72-weeks lost an average of 27.3 pounds (12.4%). One of Foundayo’s™ biggest advantages over Novo Nordisk’s existing Wegovy™ (semaglutide) oral medication is that Foundayo™ can be taken at any time of day regardless of eating habits, whereas Wegovy™ tablets must be taken only on an empty stomach 30 minutes before breakfast. Notwithstanding this and as reported by Scientific American®, “Orforglipron showed higher rates of adverse side effects such as nausea, vomiting and other gastrointestinal issues compared with semaglutide. More people discontinued orforglipron during the trial than those who stopped taking semaglutide, too”.
According to Eli Lilly, “The most common side effects of Foundayo™ include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo.”
In various studies performed during the past ~2 years, DehydraTECH has already been evaluated orally with semaglutide, liraglutide, and tirzepatide and has successfully reduced side effects with each drug. For example, in Study GLP-1-H24-4, Lexaria reported a 47.9% reduction in the total quantity of adverse events derived from oral DehydraTECH-semaglutide vs. Rybelsus™.
Lexaria has also announced plans to conduct DehyrdaTECH-processed GLP-1 testing in 2026 with additional GLP-1 drugs not previously evaluated, including retatrutide and amycretin, and is considering testing DehydraTECH-processed orforglipron as well. Lexaria believes that reducing adverse events in the GLP-1 drug sector is a significant competitive advantage enjoyed by DehydraTECH technology, which is now backed by 65 issued patents around the world.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic – Head of Investor Relations
Phone: 250-765-6424, ext 202
Uncategorized
Timothy A. Sawyer Delivers a Gripping Tale of Revenge and Redemption in New Thriller Nick’s Blunder
CRESTVIEW HILLS, KYAuthor Timothy A. Sawyer announces the release of Nick’s Blunder, a fast-paced crime thriller that weaves together a decades-old promise, a ruthless drug cartel, and one man’s relentless quest for justice. This debut novel introduces readers to a world where loyalty is tested, secrets run deep, and one wrong move can cost everything. The […]
CRESTVIEW HILLS, KY
Author Timothy A. Sawyer announces the release of Nick’s Blunder, a fast-paced crime thriller that weaves together a decades-old promise, a ruthless drug cartel, and one man’s relentless quest for justice. This debut novel introduces readers to a world where loyalty is tested, secrets run deep, and one wrong move can cost everything.

The story begins five years ago in Central California, where a drug raid gone wrong at a suspected meth lab ends in a devastating explosion. The blast takes the lives of an innocent woman and her young daughter, leaving behind her grieving husband, Jesse Schild, and police officer Frank Price. Determined to see justice done, Price vows to keep pursuing the man responsible Kirill Nikitin, leader of a sprawling international drug operation until he is brought down.
Today, Frank leads a handpicked task force to dismantle Nikitin’s empire. A brave undercover officer, a lucky break, and an unlikely alliance with Jesse bring him closer to his target. But Nikitin is no faceless kingpin: he’s a ruthless tactician who tolerates no failure and eliminates liabilities. As bodies pile up and loyalties shift, Frank and Jesse face a deadly game of cat and mouse, with their loved ones at risk.
Nick’s Blunder explores more than crime and punishment: officers’ loyalty, ordinary people’s courage in extraordinary circumstances, and the healing power of second chances. Drawing on his IT background and lifelong love of storytelling, Sawyer creates an emotionally resonant, suspenseful narrative.
The novel also pays tribute to the author’s late companion, Wendy, a faithful four-legged friend who showed him what unconditional love is all about, and to his readers and Facebook friends who continue to inspire his work. With its sharp dialogue, intricate plotting, and unforgettable characters, Nick’s Blunder marks the arrival of a compelling new voice in crime fiction.
Nick’s Blunder is available now on Amazon in eBook, Paperback, and Hardcover formats.
About the Author
Timothy A. Sawyer is an independent author based in Crestview Hills, Kentucky. After a career in information technology, he discovered a passion for writing and has since authored three self-help books along with his debut novel, Nick’s Blunder. He holds a Bachelor of Science degree from Southern New Hampshire University and is currently pursuing a master’s degree at Northern Kentucky University. He is a member of the Alpha Sigma Lambda and Delta Mu Delta honor societies and can often be found over a chessboard when he isn’t writing.
Author Name: Timothy A. Sawyer
Book Title: Nick’s Blunder
Published By: Global Author Publishing
Media Contact Details
Timothy A. Sawyer
Email: Send Email
Uncategorized
EASE Automations Completes Multi-Year TDM Modernization Initiative Across 300+ Collocations
CHICAGO, IL, October 14, 2026EASE Automations supported a multi-year telecommunications modernization initiative targeting approximately $60 million in annual recurring leased transport cost reductions.
EASE Automations supported a multi-year telecommunications modernization initiative targeting approximately $60 million in annual recurring leased transport cost reductions.
CHICAGO, IL, October 14, 2026
EASE Automations, a strategic telecommunications workforce, network transformation, and managed-services partner, announced the completion of its multi-year engagement supporting a Time Division Multiplexing (TDM) Emulation initiative for a leading wholesale voice and Communications Platform as a Service (CPaaS) provider.

The initiative began in 2023 and gained significant momentum in 2024 as EASE Automations expanded its role and team. From 2023 through 2025, the company deployed a specialized team that grew to approximately 35–40 telecommunications professionals, supporting network provisioning, circuit design, implementation, carrier coordination, validation, and legacy transport retirement.
The initiative was designed to eliminate approximately $5 million per month in leased TDM transport expenses, representing a targeted reduction of approximately $60 million in annual recurring costs. According to EASE Automations, these figures reflect the program’s cost-reduction objectives rather than independently verified realized savings.
Across more than 300 collocation environments, EASE-supported professionals designed and provisioned the IP and TDM connectivity required to bring interconnections closer to the carrier edge, backhaul traffic over IP, and support the retirement of leased TDM transport.
“Modernizing a carrier network is not simply about installing new technology,” said Stan Scott, Managing Director of EASE Automations. “The real work is making every interconnection, carrier order, provisioning dependency, activation, and cutover line up without disrupting the business. EASE Automations built and sustained a team that could operate in that complexity at scale.”
Throughout the engagement, EASE professionals collaborated with carrier organizations, internal engineering teams, vendors, and network operations personnel to move locations from design through activation. The team provided specialized expertise in carrier-scale network provisioning, circuit design and order management, TDM-to-IP enablement, implementation coordination, network validation, and legacy transport retirement.
A key component of the initiative was maintaining operational continuity throughout the transformation process. As EASE Automations’ responsibilities expanded, its professionals developed institutional knowledge of the client’s network infrastructure, provisioning processes, carrier relationships, and operational dependencies. Retaining this expertise helped sustain project execution as the modernization effort progressed.
The completed engagement highlights EASE Automations’ role in supporting large-scale telecommunications modernization through specialized workforce deployment and operational coordination. By assembling and sustaining dedicated telecommunications teams, the company supported complex network transformation activities while helping maintain the technical knowledge, coordination, and operational continuity necessary for implementation.
About EASE Automations
EASE Automations is a Chicago-based telecommunications workforce, network transformation, and managed-services partner specializing in complex network modernization projects. The company combines carrier-domain expertise with dedicated technical teams to help telecommunications organizations modernize infrastructure while maintaining operational continuity. Its capabilities include network provisioning, circuit design, implementation coordination, carrier management, TDM-to-IP enablement, network validation, and legacy transport retirement.
For more information, visit https://easeautomations.com/.
Media Contact Details
Stan Scott, Managing Director
EASE Automations
Email: Send Email
Phone: +1 (312) 803-4808
Website: easeautomations.com
Uncategorized
COLLAPSE OF THE SECRET DOMINION SETS A $200 BILLION HEIR AGAINST A GLOBAL NETWORK OF WEALTH ABUSERS
NEW YORK, NYCraig Hickman’s thriller pairs international espionage with a rebellion against financial exploitation, corruption and concealed power.
Craig Hickman’s thriller pairs international espionage with a rebellion against financial exploitation, corruption and concealed power.
NEW YORK, NY
An heir to a $200 billion empire becomes an adversary of elites bent on controlling humanity in Craig Hickman’s Collapse of the Secret Dominion. Centered on Wilson Fielder and his wife, Emily, the thriller brings a family under attack into a global struggle against the Divitiae, also known as the Wealth Abusers. Its central conflict connects extraordinary private wealth with the danger of unchecked public influence.

Missile strikes shatter Wilson and Emily’s life on a Greek isle. The attack compounds an already grave family crisis: Wilson’s father lies in a coma after an assassination attempt, and Emily has narrowly escaped abduction. Facing a conspiracy whose ambitions extend far beyond their own lives, the couple gathers revolutionaries from around the world into a resistance group, the Mundi Liberatores. Their mission takes them into bastions of European wealth, the hidden dimensions of Sino-Russian-Indian ambitions, and the complex relationships of the United States and its neighboring countries. Infiltration and investigation bring global espionage together with financial manipulation. As the group uncovers the consequences of abused wealth, power and influence, its campaign becomes a race to stop the Divitiae before society reaches a point of irreversible decay.
Wilson’s inheritance gives the confrontation a distinctive tension. The figure challenging the Wealth Abusers is himself the heir to an immense fortune, rather than someone remote from the world of concentrated wealth. That juxtaposition places privilege and resistance within the same central character. The premise sets the scale of his family’s resources beside a wider question about how wealth becomes an instrument of domination.
For readers drawn to conspiracy thrillers, the book offers an opposition that operates through both hidden networks and financial leverage. Its international scope extends the threat beyond a single government or location, while the attacks on Wilson’s family give that broad conflict a personal point of entry. The combination makes money and influence central to the danger, alongside the violence directed at those caught in the conspiracy.
The novel’s framing also gives its rebellion an explicitly ethical focus: rejecting oppressive control, resisting predatory exploitation and exposing calculated deceit. These concerns distinguish the struggle from a pursuit of one enemy alone. The Divitiae embodies abuses that reach across borders, and the Mundi Liberatores represents an effort to confront those abuses through an equally international alliance. Beyond survival and exposure, the resistance seeks the restoration of justice, equity and trust. Those aims establish what is at stake in the book’s vision of a world damaged by avarice and corruption.
Collapse of the Secret Dominion ties its thriller premise to the unresolved question of whether organized resistance can loosen entrenched power’s grip before the damage becomes irreversible.
Craig Hickman spent forty-five years inside the rooms where power operates, advising CEOs and Senior Executives of the world’s most powerful institutions as a New York Times bestselling author, Harvard MBA, and former CEO. He wrote twenty books trying to capture what he witnessed: Empowerment vs. Control; Reciprocity vs. Exploitation; Integrity vs. Deceit, revealing the full spectrum of leadership at the highest levels.
Eventually he realized that nonfiction couldn’t tell the whole truth. Fiction could, and, in his view, only fiction could do it without restraint. His shift from business books to political thrillers led to The Insiders Universe, which channels decades of insider experience into fiction. Collapse of the Secret Dominion explores how wealth, influence and concealed power can be used to dominate, and how resistance can form in response.
Available now. Get your copy here:
https://www.amazon.com/dp/1966074387
For interviews, review copies, or media inquiries, please contact:
Media Contact Details
Craig Hickman
BrightKey PR
Email: Send Email
-
Uncategorized1 year agoKirill Dmitriev: Global Investment Strategist and Architect of International Partnership
-
Uncategorized10 months agoEscape Timeshare Fees Releases Consumer Guidance on Interpreting BBB Profiles in the Timeshare Exit Industry
-
Uncategorized1 year ago
Live with Purpose Ranked #1 Show in Binge Networks’ Top 10 for July
-
Uncategorized10 months agoTreasureNFT: Partnering with BlackRock Capital for a Major Upgrade – NOVA Platform Aims to Become the World’s Largest NFT Trading Ecosystem
-
Uncategorized2 months ago
Legal Complaint Filed Against Rwandan Government Over Secret $404.7 Million Road Contract Awarded to Ruling Party’s Business Conglomerate
-
Entertainment & Sports2 years agoRachael Sage Releases Powerful Reimagined Acoustic Album, Another Side
-
Business2 years agoAivista Quant Capital CEO Dr. Smith: Tariff Policies Trigger Wrongful Sell-Off in Quality Assets, ETH Below $1,400 Severely Undervalued, Targeting Over $4,500 by Year-End
-
Business2 years agoGlobal Academic Excellence with XI TING’s Professional Tutor Team
